FrancophonIA/ELRC3.0 huggingface dataset:
English: f Includes one case of nephrotic syndrome
Slovenian: f Vključuje en primer nefrotičnega sindroma.
English: Other medicines and Cyramza
Slovenian: Druga zdravila in zdravilo Cyramza
English: Aspirin use at doses up to 325 mg/day was permitted (see section 5.1).
Slovenian: Dovoljena je bila uporaba zdravila Aspirin v odmerkih do 325 mg/dan (glejte poglavje 4.4).
English: - Abnormal urine test (‘proteinuria'): Cyramza may increase the risk of developing or worsening of abnormal levels of protein in the urine.
Slovenian: Nenormalni rezultati urinskega testa („proteinurija“): Zdravilo Cyramza lahko poveča tveganje za razvoj ali poslabšanje nenormalnih ravni beljakovin v urinu.
English: Table 5 provides details of dose delays or dose reductions of components of FOLFIRI at the next cycle based on maximum grade of specific adverse drug reactions.
Slovenian: V Tabeli 5 so navedene podrobnosti glede zamika ali zmanjšanja odmerkov posameznih komponent sheme FOLFIRI ob naslednjem ciklu, ob upoštevanju najvišjega razreda neželenih učinkov zdravila.
English: As angiogenesis is critical to maintenance of pregnancy and to foetal development, the inhibition of angiogenesis following ramucirumab administration may result in adverse effects on pregnancy, including the foetus.
Slovenian: Ker je angiogeneza ključnega pomena za ohranjanje nosečnosti in razvoj ploda, lahko zaviranje angiogeneze po dajanju ramucirumaba povzroči neželene učinke na nosečnost, vključno s plodom.
English: If you experience any symptoms affecting your ability to concentrate and react, do not drive or use machines until the effect goes away.
Slovenian: Če se pri vas pojavijo simptomi, ki bi vplivali na vašo sposobnost koncentracije in reagiranja, ne upravljajte z vozili in stroji, dokler ti učinki ne izzvenijo.
English: Based on simulations using the PopPK model, steady state would be attained by the sixth dose.
Slovenian: Na podlagi simulacij z uporabo modela populacijske farmakokinetike naj bi bilo ravnotežno stanje doseženo s šestim odmerkom.
English: Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells.
Slovenian: Ramucirumab je humano protitelo, ciljno usmerjeno na receptorje, ki se specifično veže na receptor VEGF 2 ter zavira vezavo VEGF-A, VEGFC in VEGF-D. Posledično ramucirumab zavira z ligandom stimulirano aktivacijo receptorja VEGF 2 in njegovih nadaljnjih signalnih komponent, vključno s proteinskimi kinazami p44/p42, aktiviranimi z mitogenom, nevtralizacijo z ligandom povzročene proliferacije ter migriranjem humanih endotelijskih celic.
English: What Cyramza is and what it is used for
Slovenian: Kaj je zdravilo Cyramza in za kaj ga uporabljamo
English: Includes: fatigue and asthenia.
Slovenian: Vključuje: utrujenost in astenijo.
English: However, since ramucirumab is an antiangiogenic therapy and may have the potential to adversely affect wound healing, ramucirumab treatment should be withheld for at least 4 weeks prior to scheduled surgery.
Slovenian: Ker pa je ramucirumab antiangiogeno zdravilo in lahko negativno vpliva na celjenje ran, je treba zdravljenje z ramucirumabom vsaj 4 tedne pred načrtovanim kirurškim posegom prekiniti.
English: If not used immediately, inuse storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 ºC to 8 ºC, unless dilution has taken place in controlled and validated aseptic conditions.
Slovenian: Če zdravila ne uporabite takoj, je za čas shranjevanja in pogoje pred uporabo odgovoren uporabnik; čas ne sme biti daljši od 24 ur pri temperaturi od 2 do 8 ºC, razen če je bilo redčenje opravljeno v nadzorovanih in validiranih aseptičnih pogojih.
English: Once the urine protein level has decreased to a certain level, treatment may be restarted with a lower dose.
Slovenian: Ko raven beljakovin pade do določene mere, se lahko znova uvede zdravljenje z nižjim odmerkom.
English: All medicinal products were administered intravenously.
Slovenian: Vsa zdravila so bila dana intravensko.
English: To grow, cancer needs new blood vessels to develop.
Slovenian: Da rak lahko napreduje, potrebuje za svoj razvoj nove krvne žile.
English: - have lung cancer and have had recent bleeding in the lung (coughing up bright red blood) or you are regularly taking non-steroidal anti-inflammatory medicines, or medicines which affect blood clotting ability.
Slovenian: - imate pljučni rak in ste imeli nedavno krvavitev v pljuča (izkašljevanje svetlo rdeče krvi) ali če redno jemljete nesteroidna protivnetna zdravila ali zdravila, ki vplivajo na zmožnost strjevanja krvi.
English: If patients experience symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.
Slovenian: Če se pri bolnikih pojavijo simptomi, ki vplivajo na njihovo sposobnost koncentracije in reagiranja, je priporočljivo, da z vozili in stroji ne upravljajo, dokler ti učinki ne izzvenijo.
English: Administer via infusion pump.
Slovenian: Dajajte prek infuzijske črpalke.
English: d Includes: blood pressure increased and hypertension.
Slovenian: d Vključuje: povišan krvni tlak in hipertenzijo.
English: - have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
Slovenian: - imate ali ste imeli anevrizmo (povečanje in oslabitev stene krvnih žil) ali raztrganje v steni krvnih žil.
English: Each 50 ml vial contains approximately 85 mg sodium (main component of cooking/table salt).
Slovenian: Ena 50-mililitrska viala vsebuje približno 85 mg natrija (glavne sestavine kuhinjske soli).
English: Cyramza is for intravenous use.
Slovenian: Zdravilo Cyramza je za intravensko uporabo.
English: Exposure response relationships
Slovenian: Razmerja odziva na izpostavljenost
English: Patients were required to have adequate hepatic, renal and coagulation function.
Slovenian: Bolniki so morali imeti zadovoljivo koagulacijsko funkcijo ter delovanje jeter in ledvic.
English: Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).
Slovenian: Študije na živalih niso bile zadostne, da bi dokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
English: Exposure-response analyses indicated that efficacy was correlated with ramucirumab exposure across pivotal studies.
Slovenian: Analize odziva na izpostavljenost so pokazale, da je bila učinkovitost soodnosna z izpostavljenostjo ramucirumabu v ključnih študijah.
English: Non-small cell lung cancer (NSCLC)
Slovenian: Nedrobnocelični pljučni rak (NSCLC)
English: Table 1: Criteria to be met prior to each paclitaxel administration Criteria
Slovenian: Tabela 1: Kriteriji, ki morajo biti izpolnjeni pred vsakim dajanjem paklitaksela Kriterij
English: For NCI CTCAE Grade 4 haematological toxicity or Grade 3 paclitaxel-related non-haematological toxicity, it is recommended to reduce the paclitaxel dose by 10 mg/m2 for all following cycles.
Slovenian: Za hematološko toksičnost stopnje 4 po NCI CTCAE ali za nehematološko toksičnost, povezano s paklitakselom, stopnje 3 je priporočljivo zmanjšanje odmerka paklitaksela za 10 mg/m2 za vse naslednje cikle.
English: Criteria to be met prior to each paclitaxel infusion are provided in Table 1.
Slovenian: Kriteriji, ki morajo biti izpolnjeni pred vsakim infundiranjem paklitaksela, so navedeni v Tabeli 1.
English: Based on PopPK, there was no difference in ramucirumab exposure in patients ≥65 years of age compared to patients <65 years old.
Slovenian: Na podlagi populacijske farmakokinetike niso opazili razlik v izpostavljenosti ramucirumabu pri bolnikih, starih ≥ 65 let, v primerjavi z bolniki, starimi < 65 let.
English: Ramucirumab has not been studied in patients with severe hepatic impairment (total bilirubin >3.0 ULN and any AST).
Slovenian: Ramucirumaba niso proučevali pri bolnikih s hudo okvarjenim delovanjem jeter (celokupni bilirubin > 3,0 ULN in kakršna koli vrednost AST).
English: Histidine monohydrochloride Sodium chloride Glycine (E640) Polysorbate 80 (E433) Water for injections
Slovenian: Histidinijev klorid Natrijev klorid Glicin (E640) Polisorbat 80 (E433) Voda za injiciranje
English: 11% of patients treated with Cyramza and 6% of patients on placebo discontinued therapy due to adverse events.
Slovenian: 11 % bolnikov, zdravljenih z zdravilom Cyramza, in 6 % bolnikov, ki so prejemali placebo, je zdravljenje prekinilo zaradi neželenih učinkov.
English: The recommended dose of paclitaxel is 80 mg for every square metre (m²) of your body's surface area once every week for 3 weeks followed by 1 week without treatment.
Slovenian: Priporočeni odmerek paklitaksela je 80 mg za vsak kvadratni meter (m²) površine vašega telesa enkrat na teden 3 tedne, ki jim sledi 1 teden brez zdravljenja.
English: No liver metastases: ALT/AST ≤3 x ULN Liver metastases: ALT/AST ≤5 x ULN
Slovenian: Metastaze jeter: ALT/AST ≤5 x ULN
English: If you are receiving Cyramza in combination with either paclitaxel or docetaxel on the same day, Cyramza will be given first.
Slovenian: Če prejemate zdravilo Cyramza v kombinaciji s paklitakselom ali docetakselom na isti dan, boste najprej prejeli zdravilo Cyramza.
English: Prior to chemotherapy, patients should have a complete blood count.
Slovenian: Pred kemoterapijo je treba bolnikom odvzeti kri za popolno krvno sliko.
English: See prescribing information for paclitaxel, for components of FOLFIRI and for docetaxel, as applicable, for premedication requirements and additional information.
Slovenian: Glejte navodila za predpisovanje paklitaksela, sheme FOLFIRI in docetaksela, kot je ustrezno, za pogoje premedikacije in dodatne informacije.
English: ADRs of aneurysms and artery dissections have a frequency of ‘not known'.
Slovenian: Neželeni učinki in arterijske disekcije imajo nepoznano pogostnost.
English: If you are of East Asian origin, you may receive a reduced docetaxel starting dose of 60 mg per every m2 of your body's surface area once every 3 weeks.
Slovenian: Če ste vzhodnoazijskega porekla, boste morda prejeli zmanjšan začetni odmerek docetaksela 60 mg na en m2 površine vašega telesa, enkrat na vsake 3 tedne.
English: - have severe liver disease (‘cirrhosis') and associated conditions, such as excessive accumulation of fluid in your abdomen (‘ascites').
Slovenian: - imate hudo bolezen jeter (cirozo) in povezane težave, kot je prekomerno kopičenje tekočine v vašem trebuhu (vodenica).
English: There are no data from the use of ramucirumab in pregnant women.
Slovenian: V zvezi z uporabo ramucirumaba pri nosečnicah ni podatkov.
English: - Inflammation of the mouth (‘stomatitis'): Cyramza, when given in combination with chemotherapy may increase the risk of developing inflammation of the mouth.
Slovenian: Vnetje ustne sluznice (»stomatitis«): Zdravilo Cyramza lahko v kombinaciji s kemoterapijo poveča tveganje za razvoj vnetja v ustih.
English: A majority (75%) of patients randomised in the study received prior platinum and fluoropyrimidine combination therapy without anthracycline.
Slovenian: Večina bolnikov (75 %), ki so bili vključeni v študijo, je pred tem prejemala kombinirano zdravljenje s platino in fluoropirimidinom brez antraciklina.
English: Based on PopPK, the following covariates were found to have no impact on ramucirumab disposition: age, sex, race, albumin levels.
Slovenian: Po načelih populacijske farmakokinetike so odkrili, da naslednje sospremenljivke nimajo vpliva na dispozicijo ramucirumaba: starost, spol, rasa, ravni albumina.
English: Symptoms may include sweating or other signs of infection, such as headache, pain in the limbs or decreased appetite.
Slovenian: Simptomi lahko vključujejo potenje ali druge znake okužbe, kot so npr. glavobol, bolečina v udih ali zmanjšan apetit.
English: *The 28 day time period begins on day 1 of the cycle subsequent to the ADR.
Slovenian: *28-dnevno obdobje se začne na 1. dan cikla po pojavu neželenega učinka zdravila.
English: Cyramza should not be administered or mixed with dextrose solutions.
Slovenian: Zdravila Cyramza se ne sme dajati ali mešati z raztopinami dekstroze.
English: If you experience an infusion-related reaction during treatment, the time taken to give your infusion will be increased for the rest of that infusion and for all future infusions.
Slovenian: Če se med zdravljenjem pri vas pojavi reakcija, povezana z infuzijo, bo čas dajanja vaše infuzije podaljšan ob tem in vseh prihodnjih infundiranjih.
English: e Includes: blood pressure increased, hypertension, and hypertensive cardiomyopathy.
Slovenian: e Vključuje: povišan krvni tlak, hipertenzijo in hipertenzivno kardiomiopatijo.
English: - Infusion-related reaction: Infusion-related reactions may happen during treatment because Cyramza is given as an intravenous infusion via a drip (see section 3).
Slovenian: Reakcija, povezana z infuzijo: Med zdravljenjem se lahko pojavijo reakcije, povezane z infuzijo, saj zdravilo Cyramza dajemo intravensko (kapalna infuzija) (glejte poglavje 3).
English: In both treatment arms, patients who experienced neutropenia had a longer median OS compared to patients who did not experience neutropenia.
Slovenian: V obeh skupinah zdravljenja je bilo pri bolnikih z nevtropenijo katerega koli razreda preživetje daljše kot pri bolnikih, pri katerih se nevtropenija ni pojavila.
English: Overall survival, months Median (95% CI)
Slovenian: Celokupno preživetje, meseci Mediana (95 % IZ)
English: If the patient becomes pregnant while being treated with ramucirumab, she should be informed of the potential risk to the maintenance of pregnancy and the risk to the foetus.
Slovenian: Če bolnica zanosi med zdravljenjem z ramucirumabom, je treba bolnico obvestiti o možnem tveganju za ohranitev nosečnosti in o tveganju za plod.
English: If not used immediately, inuse storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C.
Slovenian: Če zdravila ne uporabite takoj, je za čas shranjevanja in pogoje pred uporabo odgovoren uporabnik; čas ne sme biti daljši od 24 ur pri temperaturi od 2 ºC do 8 ºC.
English: What you need to know before you are given Cyramza You must not be given Cyramza
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Cyramza Ne smete prejeti zdravila Cyramza
English: The median relative dose intensity of Cyramza was 98.6% and of placebo was 99.6%.
Slovenian: Mediana intenzivnost relativnega odmerka zdravila Cyramza je znašala 98,6 %, placeba pa 99,6 %.
English: The primary QoL analysis showed similar time to deterioration for all Lung Cancer Symptom Scale (LCSS) scores between treatment arms.
Slovenian: Primarna analiza kakovosti življenja (QoL) je pri obeh skupinah zdravljenja pokazala podoben čas do poslabšanja vseh ocen na lestvicah simptomov pljučnega raka (Lung Cancer Symptom Scale; LCSS).
English: Ramucirumab therapy should be temporarily discontinued for at least 4 weeks prior to elective surgery.
Slovenian: Zdravljenje z ramucirumabom je treba začasno prekiniti vsaj 4 tedne pred načrtovanim kirurškim posegom.
English: The impact of ramucirumab has not been evaluated in patients with serious or non-healing wounds.
Slovenian: Vpliv ramucirumaba ni bil ocenjen pri bolnikih s hudimi ranami oz. z ranami, ki se ne celijo.
English: 1,200 mg/m2 over 46-48 hours a 5-FU = 5-fluorouracil.
Slovenian: 1.200 mg/m2 v 46-48 urah a 5-FU = 5-fluorouracil
English: Includes: leukopenia and white blood cell count decreased.
Slovenian: Vključuje: levkopenijo in zmanjšano število belih krvnih celic.
English: The concentrate is a clear to slightly opalescent and colourless to slightly yellow solution, pH 6.0.
Slovenian: Koncentrat je prozorna do rahlo opalescentna in brezbarvna do nekoliko rumenkasta raztopina s pH 6,0.
English: Randomisation was stratified by geographic region, tumour KRAS status (mutant or wild-type), and time to disease progression (TTP) after commencing first-line treatment (<6 months versus ≥6 months).
Slovenian: Randomizacija je bila stratificirana po geografski regiji, statusu KRAS tumorja (mutanten ali divjega tipa) in času do napredovanja bolezni po začetku zdravljenja prve izbire (< 6 mesecev v primerjavi z ≥ 6 meseci).
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Slovenian: A. IZDELOVALCI BIOLOŠKE UČINKOVINE IN IZDELOVALCI, ODGOVORNI ZA
English: The recommended dose of Cyramza for the treatment of gastric cancer, for the treatment of advanced cancer of the colon or rectum and for the treatment of liver cancer is 8 mg per kilogram of your body weight once every 2 weeks.
Slovenian: Priporočeni odmerek zdravila Cyramza za zdravljenje raka želodca, za zdravljenje napredovalega raka kolona ali rektuma in za zdravljenje raka jeter je 8 mg na kilogram vaše telesne mase enkrat na dva tedna.
English: It is unknown whether ramucirumab is excreted in human milk.
Slovenian: Ni znano, ali se ramucirumab izloča v materino mleko.
English: Cyramza can cause blood clots in your arteries.
Slovenian: Zdravilo Cyramza lahko povzroči krvne strdke v vaših arterijah.
English: Ramucirumab is an antiangiogenic therapy and may increase the risk of gastrointestinal perforations.
Slovenian: Ramucirumab je antiangiogeno zdravilo in lahko poveča tveganje za gastrointestinalne perforacije.
English: Body weight is considered a significant co-variate of ramucirumab pharmacokinetics supporting the dosing based on body weight.
Slovenian: Telesna masa velja za pomembno sospremenljivko pri farmakokinetiki ramucirumaba, kar podpira odmerjanje na podlagi telesne mase.
English: From the side effects listed above, these are: low white blood cell counts; low platelet count in the blood; low blood levels of albumin, potassium or sodium; presence of protein in the urine.
Slovenian: Izmed zgoraj naštetih neželenih učinkov so to: zmanjšanje števila belih krvničk, zmanjšanje števila krvnih ploščic, nizke ravni albumina, kalija ali natrija v krvi, prisotnost beljakovin v urinu.
English: Based on ramucirumab's mechanism of action, it is likely that in animals, ramucirumab will inhibit angiogenesis and result in adverse effects on fertility (ovulation), placental development, developing foetuses and postnatal development.
Slovenian: Glede na mehanizem delovanja ramucirumaba je verjetno, da pri živalih ramucirumab zavira angiogenezo in povzroča neželene učinke na plodnost (ovulacija), razvoj placente, razvijajoče se plodove in postnatalni razvoj.
English: There was no clear deviation from dose proportionality in pharmacokinetics of ramucirumab from 6 mg/kg to 20 mg/kg.
Slovenian: Jasnega odstopanja od sorazmernosti odmerka v farmakokinetiki ramucirumaba od 6 mg/kg do 20
English: A hospital pharmacist, nurse or doctor will have diluted the contents of the vial with sodium chloride 9 mg/ml
Slovenian: Pred uporabo bolnišnični farmacevt, medicinska sestra ali zdravnik razredči vsebino viale z 9 mg/ml
English: Patients who experience either febrile neutropenia, neutrophils <500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions, or other Grade 3 or 4 non-haematological toxicities during docetaxel treatment should have treatment withheld until resolution of the toxicity.
Slovenian: Pri bolnikih, pri katerih se med zdravljenjem z docetakselom pojavijo bodisi febrilna nevtropenija, število nevtrofilcev < 500 celic/mm3, ki traja več kot 1 teden, hude kožne reakcije ali druge nehematološke toksičnosti razreda 3 ali 4, je treba zdravljenje prekiniti, dokler toksičnost ne mine.
English: Women of childbearing potential should use effective contraception during and up to 3 months after the last dose of ramucirumab treatment.
Slovenian: Ženske v rodni dobi morajo med zdravljenjem z ramucirumabom in do 3 mesecev po zadnjem odmerku uporabljati učinkovito kontracepcijo.
English: Patients receiving any kind of therapeutic anticoagulation and/or chronic therapy with non-steroidal anti-inflammatory drugs or anti-platelet agents were excluded from the REVEL NSCLC clinical trial.
Slovenian: Bolniki, ki so prejemali katero koli vrsto terapevtske antikoagulacije in/ali kroničnega zdravljenja z nesteroidnimi protivnetnimi zdravili ali antiagregacijskimi zdravili, so bili izključeni iz kliničnega preskušanja REVEL NSCLC.
English: The most common adverse reactions observed in ramucirumab-treated patients are: neutropenia, fatigue/asthenia, leukopenia, epistaxis, diarrhoea and stomatitis.
Slovenian: Najpogostejši neželeni učinki, ki so jih opazili pri bolnikih, zdravljenih z ramucirumabom, so: nevtropenija, utrujenost/astenija, levkopenija, epistaksa, diareja in stomatitis.
English: Randomisation was stratified by geographic region, time to progression from the start of first-line therapy (<6 months versus ≥6 months) and disease measurability.
Slovenian: Randomizacija je bila stratificirana z geografsko regijo, časom do napredovanja bolezni od začetka zdravljenja prve izbire (<6 mesecev v primerjavi z ≥6 mesecev) in merljivostjo bolezni.
English: In a study conducted in animals, ramucirumab did not impair wound healing.
Slovenian: V študiji, opravljeni na živalih, ramucirumab ni poslabšal celjenja ran.
English: Based on population pharmacokinetic approach (PopPK), the mean (% coefficient of variation [CV%]) volume of distribution at steady state for ramucirumab was 5.4L (15%).
Slovenian: Po načelih populacijske farmakokinetike je povprečni (% koeficient variacije, CV) porazdelitveni volumen za ramucirumab v ravnotežnem stanju znašal 5,4 l (15 %).
English: Ramucirumab is an antiangiogenic therapy and may increase the risk of severe bleeding.
Slovenian: Ramucirumab je antiangiogeno zdravilo in lahko poveča tveganje za hudo krvavitev.
English: For patients treated with Cyramza plus paclitaxel the median duration of therapy was 19 weeks, and for patients treated with placebo plus paclitaxel the median duration of therapy was 12 weeks.
Slovenian: Pri bolnikih, zdravljenih z zdravilom Cyramza in paklitakselom, je bilo mediano trajanje zdravljenja 19 tednov, pri bolnikih, zdravljenih s placebom in paklitakselom, pa je bilo mediano trajanje zdravljenja 12 tednov.
English: Ramucirumab in combination with FOLFIRI
Slovenian: Ramucirumab v kombinaciji s shemo FOLFIRI
English: Cyramza is a cancer medicine that contains the active substance ramucirumab, which is a monoclonal antibody.
Slovenian: Cyramza je zdravilo proti raku, ki vsebuje učinkovino ramucirumab, ki je monoklonsko protitelo.
English: The primary endpoint was OS and the secondary endpoints included PFS, objective response rate (ORR) and quality of life (QoL) using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.
Slovenian: Primarni opazovani dogodek je bilo celokupno preživetje (OS), sekundarni opazovani dogodki pa so vključevali preživetje brez napredovanja bolezni (PFS), objektivno stopnjo odziva (ORR) in kakovost življenja, ocenjeno z uporabo vprašalnika Evropske organizacije za raziskave in zdravljenje raka (European Organisation for Research and Treatment of Cancer; EORTC) QLQ-C30.
English: Cyramza can increase the incidence of high blood pressure.
Slovenian: Zdravilo Cyramza lahko poveča pojavnost visokega krvnega tlaka.
English: Do not administer the solution if you notice any particulate matter or discolouration.
Slovenian: Ne dajajte raztopine, če opazite v njej delce ali obarvanost.
English: Based on PopPK, the mean (CV%) clearance of ramucirumab was 0.015 L/hour (30%) and the mean half-life was 14 days (20%).
Slovenian: Po načelih populacijske farmakokinetike je bil povprečni (CV %) očistek ramucirumaba 0,015 l/uro (30 %), povprečen razpolovni čas pa je znašal 14 dni (20 %).
English: Depending on the protein level measured, Cyramza may be temporarily discontinued.
Slovenian: Glede na izmerjeno raven beljakovin bo zdravljenje z zdravilom Cyramza morda treba začasno prekiniti.